Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Robot takes the scalpel: new study tests hugo system for cancer surgeries

NCT ID NCT05696444

Disease control Sponsor: Medtronic - MITG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well a new robotic surgery system (Medtronic Hugo) works for urologic procedures like removing prostate, bladder, or kidney tumors. About 144 adults will have surgery with the robot, and doctors will check if the surgery is completed without switching to another method and track any complications within 30 days. The goal is to see if the system is safe and effective for these common cancer surgeries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

144 people

The number who actually took part.

Started

Dec 2022

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult subjects (age ≥ 22 years) as required by local law 2. Subject has been indicated for a radical prostatectomy, radical cystectomy, or nephrectomy (partial or radical) surgical procedure 3. Subject is an acceptable candidate for a fully robotic assisted surgical procedure, a laparoscopic surgical procedure, or an open surgical procedure 4. The subject is willing to participate and consents to participate, as documented by a signed and dated informed consent form Exclusion Criteria: 1. Subjects for which minimally invasive surgery is contraindicated as determined by the Investigator 2. Subjects with comorbidities or medical characteristics, which would preclude the surgical procedure in the opinion of the Investigator 3. Subjects diagnosed with a bleeding disorder and/or cannot be removed from their anticoagulants prior to surgery based on surgeon discretion and standard-of-care 4. Non-oncology subjects with an estimated life expectancy of less than 6 months; oncology subjects considered for cystectomy with a life expectancy less than 24 months; oncology subjects considered for nephrectomy with a life expectancy less than 60 months; oncology subjects considered for prostatectomy with less than a 10-year life expectancy. 5. Female subjects pregnant at the time of the surgical procedure. 6. Subjects who are considered to be part of a vulnerable population (e.g., prisoners or those without sufficient mental capacity) 7. Subjects who have participated in an investigational drug or device research study within 30 days of enrollment that would interfere with this study 8. Subjects with active infections including but not limited to pneumonia, urinary tract, cellulitis, or bacteremia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bladder cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury chronic kidney disease Congenital Abnormalities end stage renal failure interstitial cystitis kidney cancer kidney neoplasm Pelvic Neoplasms prostate cancer renal cell carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bladder cancer Congenital abnormalities End-stage renal disease Interstitial cystitis Kidney cancer Kidney injury Pelvic tumor Prostate cancer Renal tumor

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Duke Medical Center

    Durham, North Carolina, 27710, United States

  • Mount Sinai

    New York, New York, 10029, United States

  • Swedish Medical Center

    Seattle, Washington, 98122, United States

  • University of Chiago

    Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.